Immune checkpoint inhibitors are causing a paradigm shift in cancer treatment. Immune checkpoint molecules such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) dampen T cell activation to avoid autoimmunity and the destructive effects of an excessive inflammatory response. Immune checkpoint signaling can be exploited by tumors to escape host immune surveillance, and immune checkpoint inhibitors enhance antitumor immunity by releasing the brakes on the immune system. PD-1 was identified in 1992 by Honjo and colleagues at Kyoto University. Studies in animal models revealed that PD-1 blockade can inhibit tumorigenesis and tumor metastasis. In addition, PD-1 blockade showed fewer adverse effects than CTLA-4 blockade. Based on these findings, a humanized monoclonal antibody against human PD-1 called nivolumab was developed.
and radiation therapy.
Cancer immunotherapy dates back to 1891, when William Coley, a New York surgeon, discovered that patients could recover from osteosarcoma after developing a form of cellulitis known as erysipelas 1 . He subsequently treated these patients by injecting the causative bacteria into the tumor. Only recently has this mechanism been understood and it took almost a century for the discov- 
Mechanism of Immunosuppression by PD-1
The PD-1 gene was cloned in 1992 in the Honjo Laboratory at Kyoto University 3 , and its function was subsequently determined by the same group (Fig. 1) . PD-1 is an immunoinhibitory receptor belonging to the CD28 family that is expressed on activated T cells to regulate T cell proliferation and effector function (e.g., cytokine production and cytotoxic activity) 4 . The immunosuppressive action of PD-1 was revealed using PD-1-deficient mice 5, 6 .
Depending cancer, ovarian cancer, and breast cancer 9, 15 . In contrast, expression of PD-L2 is limited to antigen-presenting cells 9 .
Antitumor Effects of Anti-PD-1/PD-L1 Antibody
After In addition, PD-1 blockade shows protective immunity against viral infection 14 .
From Basic Studies to Clinical Application
Based on the basic medical research described above, a The response duration of PD-1 blockade is long and can be maintained for more than 2 years in many cases.
PD-1 mAb therapy showed significantly better results than docetaxel as a standard therapy for patients with previously advancedsquamous cell carcinoma NSCLC in a phase III trial comparing these two therapies 22 . For example, the 1-year survival rate was 42% for PD-1 mAb and 24% for docetaxel; the response rate was 20% for PD-1 mAb and 9% for docetaxel; the response duration was still in progress for PD-1 mAb and 8.4 months for docetaxel. The trial also showed that PD-1 blockade had fewer adverse effects of grade 3 or more (i.e., 7% and 57% for PD-1 mAb and docetaxel, respectively). The esti- 
